Wheeler Bio and Mitsubishi Corporation Join Forces to Boost CDMO Expansion in Asia-Pacific

Wheeler Bio has formed a strategic partnership with Mitsubishi Corporation aimed at enhancing its business development and commercial operations across the Asia-Pacific region. As part of this collaboration, Mitsubishi Corporation will invest in Wheeler’s Series A-1 financing, becoming the exclusive commercialization partner for the company in the region.

The partnership will focus on connecting biotechnology companies in markets such as Japan, South Korea, India, Singapore, Taiwan, and China with Wheeler Bio’s advanced U.S.-based cGMP manufacturing capabilities. This initiative is expected to facilitate access to Wheeler’s AI/ML-enabled ModularCMC platform and its state-of-the-art biomanufacturing facility located in **Oklahoma City**.

Leveraging Expertise for Growth

Wheeler Bio, a contract development and manufacturing organization (CDMO) based in the United States, aims to streamline the path from discovery to clinical development for antibody-based therapeutics. The partnership with Mitsubishi is expected to enhance support for biotech innovators seeking U.S. development and cGMP manufacturing assistance.

According to **Takahiro Tokuda**, COO of the Healthcare Division at Mitsubishi Corporation, “We have long been engaged in the pharmaceutical CDMO market, and we are firmly convinced that Wheeler Bio’s service offerings will provide significant value to clients. Through this strategic partnership, we are confident that the development of biopharmaceutical seeds in the APAC region will be accelerated, ultimately contributing to the improvement of people’s lives.”

Patrick Lucy, President and CEO of Wheeler Bio, expressed enthusiasm about the partnership, stating, “Wheeler is honoured to have Mitsubishi invest in and partner with Wheeler Bio in support of our business development efforts as we scale the organization. Mitsubishi’s long-term domain experience in biologics contract manufacturing is invaluable to our growth objectives.”

Strategic Goals and Future Impact

The collaboration not only emphasizes the importance of technological advancements but also highlights the potential for significant growth in the biopharmaceutical sector within the Asia-Pacific region. By utilizing Mitsubishi’s extensive industry network and commercial expertise, Wheeler Bio aims to engage with innovative biotech firms and facilitate their development processes.

The investment from Mitsubishi Corporation marks a pivotal moment for Wheeler Bio, enabling the company to expand its reach and influence in a vital market. As the partnership progresses, both companies are poised to make impactful contributions to the healthcare landscape, ultimately benefiting patients and healthcare providers alike.

As they navigate this new venture, Wheeler Bio and Mitsubishi Corporation are set to play a crucial role in advancing biomanufacturing capabilities and fostering innovation across the Asia-Pacific biotech sector. The partnership reflects a commitment to improving lives through enhanced access to cutting-edge biopharmaceutical solutions.